Cargando…
Cathepsin B-Overexpressed Tumor Cell Activatable Albumin-Binding Doxorubicin Prodrug for Cancer-Targeted Therapy
Prodrugs are bioreversible medications that should undergo an enzymatic or chemical transformation in the tumor microenvironment to release active drugs, which improve cancer selectivity to reduce toxicities of anticancer drugs. However, such approaches have been challenged by poor therapeutic effic...
Autores principales: | Cho, Hanhee, Shim, Man Kyu, Yang, Suah, Song, Sukyung, Moon, Yujeong, Kim, Jinseong, Byun, Youngro, Ahn, Cheol-Hee, Kim, Kwangmeyung |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8780658/ https://www.ncbi.nlm.nih.gov/pubmed/35056979 http://dx.doi.org/10.3390/pharmaceutics14010083 |
Ejemplares similares
-
Tumor-Specific Monomethyl Auristatin E (MMAE) Prodrug Nanoparticles for Safe and Effective Chemotherapy
por: Cho, Hanhee, et al.
Publicado: (2022) -
Anti-PD-L1 peptide-conjugated prodrug nanoparticles for targeted cancer immunotherapy combining PD-L1 blockade with immunogenic cell death
por: Moon, Yujeong, et al.
Publicado: (2022) -
Preclinical development of carrier-free prodrug nanoparticles for enhanced antitumor therapeutic potential with less toxicity
por: Shim, Man Kyu, et al.
Publicado: (2022) -
Sustained and Long-Term Release of Doxorubicin from PLGA Nanoparticles for Eliciting Anti-Tumor Immune Responses
por: Kim, Jeongrae, et al.
Publicado: (2022) -
All-in-one glycol chitosan nanoparticles for co-delivery of doxorubicin and anti-PD-L1 peptide in cancer immunotherapy
por: Song, Sukyung, et al.
Publicado: (2023)